Sentences with phrase «third party reimbursement in»

Mission Statement: The CATA COPA is to provide and ensure continued opportunity for an athletic trainers to receive third party reimbursement in the State of Connecticut.

Not exact matches

These risks and uncertainties include, among others: the unfavorable outcome of litigation, including so - called «Paragraph IV» litigation and other patent litigation, related to any of our products or products using our proprietary technologies, which may lead to competition from generic drug manufacturers; data from clinical trials may be interpreted by the FDA in different ways than we interpret it; the FDA may not agree with our regulatory approval strategies or components of our filings for our products, including our clinical trial designs, conduct and methodologies and, for ALKS 5461, evidence of efficacy and adequacy of bridging to buprenorphine; clinical development activities may not be completed on time or at all; the results of our clinical development activities may not be positive, or predictive of real - world results or of results in subsequent clinical trials; regulatory submissions may not occur or be submitted in a timely manner; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to governmental payers; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading «Risk Factors» in the company's most recent Annual Report on Form 10 - K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission («SEC»), which are available on the SEC's website at www.sec.gov.

Such risks, uncertainties and other factors include, without limitation: (1) the effect of economic conditions in the industries and markets in which United Technologies and Rockwell Collins operate in the U.S. and globally and any changes therein, including financial market conditions, fluctuations in commodity prices, interest rates and foreign currency exchange rates, levels of end market demand in construction and in both the commercial and defense segments of the aerospace industry, levels of air travel, financial condition of commercial airlines, the impact of weather conditions and natural disasters and the financial condition of our customers and suppliers; (2) challenges in the development, production, delivery, support, performance and realization of the anticipated benefits of advanced technologies and new products and services; (3) the scope, nature, impact or timing of acquisition and divestiture or restructuring activity, including the pending acquisition of Rockwell Collins, including among other things integration of acquired businesses into United Technologies» existing businesses and realization of synergies and opportunities for growth and innovation; (4) future timing and levels of indebtedness, including indebtedness expected to be incurred by United Technologies in connection with the pending Rockwell Collins acquisition, and capital spending and research and development spending, including in connection with the pending Rockwell Collins acquisition; (5) future availability of credit and factors that may affect such availability, including credit market conditions and our capital structure; (6) the timing and scope of future repurchases of United Technologies» common stock, which may be suspended at any time due to various factors, including market conditions and the level of other investing activities and uses of cash, including in connection with the proposed acquisition of Rockwell; (7) delays and disruption in delivery of materials and services from suppliers; (8) company and customer - directed cost reduction efforts and restructuring costs and savings and other consequences thereof; (9) new business and investment opportunities; (10) our ability to realize the intended benefits of organizational changes; (11) the anticipated benefits of diversification and balance of operations across product lines, regions and industries; (12) the outcome of legal proceedings, investigations and other contingencies; (13) pension plan assumptions and future contributions; (14) the impact of the negotiation of collective bargaining agreements and labor disputes; (15) the effect of changes in political conditions in the U.S. and other countries in which United Technologies and Rockwell Collins operate, including the effect of changes in U.S. trade policies or the U.K.'s pending withdrawal from the EU, on general market conditions, global trade policies and currency exchange rates in the near term and beyond; (16) the effect of changes in tax (including U.S. tax reform enacted on December 22, 2017, which is commonly referred to as the Tax Cuts and Jobs Act of 2017), environmental, regulatory (including among other things import / export) and other laws and regulations in the U.S. and other countries in which United Technologies and Rockwell Collins operate; (17) the ability of United Technologies and Rockwell Collins to receive the required regulatory approvals (and the risk that such approvals may result in the imposition of conditions that could adversely affect the combined company or the expected benefits of the merger) and to satisfy the other conditions to the closing of the pending acquisition on a timely basis or at all; (18) the occurrence of events that may give rise to a right of one or both of United Technologies or Rockwell Collins to terminate the merger agreement, including in circumstances that might require Rockwell Collins to pay a termination fee of $ 695 million to United Technologies or $ 50 million of expense reimbursement; (19) negative effects of the announcement or the completion of the merger on the market price of United Technologies» and / or Rockwell Collins» common stock and / or on their respective financial performance; (20) risks related to Rockwell Collins and United Technologies being restricted in their operation of their businesses while the merger agreement is in effect; (21) risks relating to the value of the United Technologies» shares to be issued in connection with the pending Rockwell acquisition, significant merger costs and / or unknown liabilities; (22) risks associated with third party contracts containing consent and / or other provisions that may be triggered by the Rockwell merger agreement; (23) risks associated with merger - related litigation or appraisal proceedings; and (24) the ability of United Technologies and Rockwell Collins, or the combined company, to retain and hire key personnel.

In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third - party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment.

In particular, as disclosed in filings with the U.S. Securities and Exchange Commission, Amarin's ability to effectively develop and commercialize Vascepa will depend in part on its ability to continue to effectively finance its business, efforts of third parties, its ability to create market demand for Vascepa through education, marketing and sales activities, to achieve increased market acceptance of Vascepa, to receive adequate levels of reimbursement from third - party payers, to develop and maintain a consistent source of commercial supply at a competitive price, to comply with legal and regulatory requirements in connection with the sale and promotion of Vascepa and to maintain patent protection for VascepIn particular, as disclosed in filings with the U.S. Securities and Exchange Commission, Amarin's ability to effectively develop and commercialize Vascepa will depend in part on its ability to continue to effectively finance its business, efforts of third parties, its ability to create market demand for Vascepa through education, marketing and sales activities, to achieve increased market acceptance of Vascepa, to receive adequate levels of reimbursement from third - party payers, to develop and maintain a consistent source of commercial supply at a competitive price, to comply with legal and regulatory requirements in connection with the sale and promotion of Vascepa and to maintain patent protection for Vascepin filings with the U.S. Securities and Exchange Commission, Amarin's ability to effectively develop and commercialize Vascepa will depend in part on its ability to continue to effectively finance its business, efforts of third parties, its ability to create market demand for Vascepa through education, marketing and sales activities, to achieve increased market acceptance of Vascepa, to receive adequate levels of reimbursement from third - party payers, to develop and maintain a consistent source of commercial supply at a competitive price, to comply with legal and regulatory requirements in connection with the sale and promotion of Vascepa and to maintain patent protection for Vascepin part on its ability to continue to effectively finance its business, efforts of third parties, its ability to create market demand for Vascepa through education, marketing and sales activities, to achieve increased market acceptance of Vascepa, to receive adequate levels of reimbursement from third - party payers, to develop and maintain a consistent source of commercial supply at a competitive price, to comply with legal and regulatory requirements in connection with the sale and promotion of Vascepa and to maintain patent protection for Vascepin connection with the sale and promotion of Vascepa and to maintain patent protection for Vascepa.

The Practice Advancement Committee is responsible for educating and updating the membership on the issues pertaining to third - party reimbursement, employment, and other revenue issues for athletic trainers in the state of Wisconsin.

In conjunction with state and national leadership, we have developed a well designed strategic plan to advance third party reimbursement initiatives in the State of Wisconsin that will implement diverse pilot programs at key locations around the statIn conjunction with state and national leadership, we have developed a well designed strategic plan to advance third party reimbursement initiatives in the State of Wisconsin that will implement diverse pilot programs at key locations around the statin the State of Wisconsin that will implement diverse pilot programs at key locations around the state.

Please be patient with this process as we want to create a well designed and coordinated roadmap for those athletic trainers and employers that wish to pursue third party reimbursement for athletic trainers under the athletic training scope of practice in the State of Wisconsin.

Committee Co-Coordinators: Brent Amble and Mark Husen Purpose: Educating and updating the membership on the issues pertaining to third - party reimbursement, employment, and other revenue issues for athletic trainers in the State of Wisconsin.

Working with Eric Hall to put together the proposal submitted and ultimately selected (one of three) to participate in the NATA Third - party Reimbursement Pilot Program.

«The current program demonstrated that school - based third - party billing for both vaccine and implementation costs was feasible, but problems with reimbursement will need to be solved before it can be financially solvent,» the authors wrote in an article published in the May - June 2014 issue of Academic Pediatrics.

This study also provides robust data for third - party payers or government agencies in an era in which physician performance metrics require valid risk adjustment before being used for reimbursement and quality initiatives.

These benefits may warrant third - party reimbursement for this intervention in selected patients.

These risks and uncertainties include, among others, those relating to our ability to obtain financing and to form collaborative relationships, uncertainty regarding potential future deterioration in the market for auction rate securities which could result in additional permanent impairment charges, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10 - Q or Current Reports on Form 8 - K.

These risks and uncertainties include, among others, those relating to our ability to obtain sufficient financing to continue as a going concern, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, our ability to form collaborative relationships, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10 - Q or Current Reports on Form 8 - K.

These risks and uncertainties include, among others, those relating to our ability to obtain sufficient financing to continue as a going concern, the outcome of the review of the continued listing of our common stock on The Nasdaq Stock Market, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, our ability to form collaborative relationships, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10 - Q or Current Reports on Form 8 - K.

The Neuroimaging Center is accelerating the rate of research advances by gathering objective evidence of a treatment's success in an effort to make a case for third - party reimbursement and make the treatment widely accessible to those who need it.

32/25 Highway / City MPGNissan Certified Pre-Owned Details: * 167 Point Inspection * Warranty Deductible: $ 50 * Roadside Assistance * Vehicle History * Includes Car Rental and Trip Interruption Reimbursement * Powertrain Limited Warranty: 84 Month / 100, 000 Mile (whichever comes first) from original in - service date * Transferable Warranty (between private parties) Awards: * 2015 IIHS Top Safety PickReviews: * Smooth highway ride, optional third - row seating, user - friendly tech options, upscale look and feel, versatile interior storage.

32/25 Highway / City MPGNissan Certified Pre-Owned Details: * Includes Car Rental and Trip Interruption Reimbursement * Powertrain Limited Warranty: 84 Month / 100, 000 Mile (whichever comes first) from original in - service date * Vehicle History * Warranty Deductible: $ 50 * Roadside Assistance * 167 Point Inspection * Transferable Warranty (between private parties) Awards: * 2016 IIHS Top Safety Pick * 2016 10 Best SUVs Under $ 25,000 Reviews: * Smooth highway ride, optional third - row seating, user - friendly tech options, upscale look and feel, versatile interior storage.

32/25 Highway / City MPGNissan Certified Pre-Owned Details: * Roadside Assistance * Includes Car Rental and Trip Interruption Reimbursement * Warranty Deductible: $ 50 * Powertrain Limited Warranty: 84 Month / 100, 000 Mile (whichever comes first) from original in - service date * Vehicle History * 167 Point Inspection * Transferable Warranty (between private parties) Awards: * 2015 IIHS Top Safety PickReviews: * Smooth highway ride, optional third - row seating, user - friendly tech options, upscale look and feel, versatile interior storage.

32/25 Highway / City MPGNissan Certified Pre-Owned Details: * 167 Point Inspection * Warranty Deductible: $ 50 * Includes Car Rental and Trip Interruption Reimbursement * Vehicle History * Powertrain Limited Warranty: 84 Month / 100, 000 Mile (whichever comes first) from original in - service date * Transferable Warranty (between private parties) * Roadside AssistanceAwards: * 2015 IIHS Top Safety PickReviews: * Smooth highway ride, optional third - row seating, user - friendly tech options, upscale look and feel, versatile interior storage.

Finally, Ally Interest Checking comes with no monthly fees, no fees for overdraft transfers and up to $ 10 in reimbursements for third - party ATM surcharges.

The credit union also provides up to $ 15 a month in reimbursements for any fees you pay at ATMs, including surcharges from third - party operators.

LAwPRO counsel also participate in seeking resolution of many claims via negotiation, mediation and arbitration; and take all reasonable steps to recover costs, through the enforcement of judgments and costs orders, and by pursuing reimbursement from third parties.

While you may not have noticed, it is likely that your health insurance company included subrogation (i.e., reimbursement) language in your health insurance contract which gives them the right to be reimbursed if you are injured by a third party (i.e., the person who caused the accident).

She has helped minimise the impact of an ongoing third - party labour dispute at its local manufacturing plant, as well as being instrumental in negotiating reimbursement for costs incurred defending the dispute.

Comment: One commenter recommended clarifying in the final rule that the government health data system provisions apply to: (1) Manufacturers providing data to HCFA and its contractors to help the agency make reimbursement and related decisions; and to (2) third - party payors that must provide data collected by device manufacturers to HCFA to help the agency make reimbursement and related decisions.

[47] The Reimbursement Agreement binds the appellant to make the repayment called for in the Plan, hence, repayment of a portion of any lump sum cash payment made upon or contingent upon resolution of a claim for compensation made against a Third Party.

Accidental death benefits is also in this plan and third party reimbursement too.

Register your claim with HDFC ERGO inhouse claims services team (HCS) / Third Party Administrator (TPA) for processing and reimbursement by submitting duly filled claim form along with required documents as mentioned in the claim form.

Formalities for a health insurance claim You can make a claim under a Health insurance policy in two ways: On a Cashless basis and A Reimbursement Claim On a Cashless basis: For a claim on cashless basis, your treatment must be only at a network hospital of the Third Party Administrator (TP...

Skills / Requirements: * 3 years experience in medical billing and reimbursement, posting and reconciling third party medical payments is REQUIRED.

Oversaw collections, third - party verification, reimbursement solutions in order to meet GEICO's standard procedures

Needs a bachelor's degree and two years» experience in third party reimbursement.

Medical Coding Training: The online medical billing classes offered by the AAPC are aimed at teaching you the ins and outs of the medical billing industry, including the process of claims submission and Medicare, Medicaid, and third - party reimbursement.

Owner of the MDF program process with several alliance partners, which included but not limited to partnering with internal teams and third party partners to ensure all transactions were accurate and processed in a timely manner including pre-approvals, claims, invoicing and payments of all MDF reimbursements via SharePoint

Acted as a liaison between the business department billers and third party payers in resolving billing and reimbursement accuracy.

Consistently ensured proper coding, sequencing of diagnoses and procedures.Quickly responded to staff and client inquiries regarding CPT codes.Acted as a liaison between the business department, billers and third party payers in resolving billing and reimbursement accuracy.

2 + years retail, mail order, long - term care hospital experience as a Pharmacy Technician - includes experience in dealing with: - Insurance benefits authorization - Prior Authorization approvals - Adjudications issues - Coverage verification - Reimbursement issues - Claim processing - Data entry of prescriptions - Dispensing prescriptions, 2 + years customer service experience in an organization providing superior customer service handling: - Outbound calls to customers, doctor offices, third party administrators, coordinating insurance billing, verifying coverage, resolving insurance coverage issues, and obtaining prior authorization approvals.

Winthrop University Hospital (Mineola, NY) 2003 — 2006 Surgical Specialist • Assisted in the booking and scheduling of all surgical, medical, and diagnostic procedures for 8 doctors within a cardiovascular and thoracic practice • Maximized third - party reimbursement for both new and experimental procedures by 11 % • Initiated a thorough appeals process on all denied claims, increasing pay rates by 20 % • Aided in other administrative and operational functions associated with surgical procedure management

Medical Billing Specialist — Duties & Responsibilities Manage medical billing, coding, and customer service operation for industry leading corporations Develop extensive experience with all major medical insurance providers Provide exceptional customer service resulting in 100 % client satisfaction rating Maximize reimbursements and minimize costs through effective management Serve as member of Rate Book Committee overseeing 80,000 outpatient third party accounts Recruit, hire, and train staff ensuring understanding of company brand, policies, and procedures Responsible for $ 100 million per year in company income and company record of $ 46 million in one month Oversee financial management providing best practices and strategic planning Build and strengthen relationships with third party payors including Medicare, Medicaid, and others Author and present reports to senior leadership regarding company financial health Set and strictly adhere to departmental budgets and project timelines Ensure compliance with applicable laws and industry regulations Establish and maintain detailed records regarding claims, billing, and client information Create and implement clinical and nonclinical team training activities Consistently promoted for excellence in management, customer service, and revenue generation Study internal literature to become an expert on products and services Represent company brand with poise, integrity, and positivity

AFLAC (Columbus, GA) 10/2008 — 7/2009 Claims Specialist • Assisted in the booking and scheduling of all surgical, medical, and diagnostic procedures for 8 doctors within a cardiovascular and thoracic practice • Maximized third - party reimbursement for both new and experimental procedures by 11 % • Initiated a thorough appeals process on all denied claims, increasing pay rates by 20 % • Aided in other administrative and operational functions associated with surgical procedure management

Under the existing legislative regime, PBCs are not able to seek reimbursement from or charge third parties for cost and disbursements expended or incurred (or estimated to be expended or incurred) by the PBC in performing its functions under the NTA or the PBC Regulations.

Allows for PBCs to seek reimbursement from or charge third parties for costs and disbursements expended or incurred in performing statutory functions under the NTA or PBC regulations.

If parents request payments for supplemental reimbursement in addition to the standard adoption assistance payment rate, the adoption social worker provides relevant documentation describing ongoing, additional expenses that are paid above the current foster care rate and which are not expected to be absorbed by other resources, services, or third party payments following the final decree of adoption.